ARCHIVES

Phase III Five-Year Data Show Erbitux Increases Survival Of Head And Neck Cancer

This article is from The Cancer Letter archive.

Vol. 31 No. 9 | September 26, 2008

Download PDF Visit The Full Archive

Related Articles

Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies

November 28, 2014

FTC Cigarette Test Should Be Broadened, Cancer Panel Finds

December 16, 1994

NCI To Seek Proposals For Less Invasive Detection, Diagnosis, Treatment Technologies

July 3, 1998

National Dialogue On Cancer, The Cancer Act, And Activism.

February 4, 2000

DCBDC Advisors Okay New Program In Breast Cancer

July 3, 1992

EntreMed Issued U.S. Patent For Active Parts Of Endostatin.

March 2, 2001